After an official request from Edwards Lifesciences, CMS is rethinking its coverage policy for the use of TAVR to treat asymptomatic severe aortic stenosis. The agency is accepting public comments on this topic until Jan. 14. 

Improvements in care have resulted in a growing number of patients who go on to be diagnosed with both cancer and severe aortic stenosis. TAVR appears to be an effective treatment option for those individuals, and it may help them go on to receive life-saving cancer therapies.

Hospitals located in more competitive markets may be more likely to perform TAVR instead of SAVR, according to a new analysis of more than 130,000 patients. Is this a reason for concern?

While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.

The sensor-guided device delivers continuous hemodynamic measurements and rapid left ventricular pacing during TAVR procedures. Back in 2023, it was at the heart of a $253 million acquisition. 

A fifth-generation TAVR valve from Edwards Lifesciences was associated with improved outcomes compared to the device's predecessors in a new real-world analysis out of Cedars Sinai.

Advanced AI technologies are starting to play a bigger role in TAVR care, helping cardiologists plan ahead, make critical decisions and predict potential complications. Looking to the future, though, it is clear this is just the beginning.